CD36: A multi-modal target for acute stroke therapy

Journal of Neurochemistry

Volumn 109, Issue SUPPL. 1, 2009, Pages 126-132

  Cho, Sunghee ^a,b,c   Kim, Eunhee ^b  

^a Burke Cornell Medical Research Institute   (United States)

^b BURKE MEDICAL RESEARCH INSTITUTE   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Cerebral ischemia; Inflammation; Neuroprotection; Risk factor; Stroke

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; CD36 ANTIGEN; EP80317; HEXARELIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PEPTIDE; PEPTIDE SS31; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTIGEN EXPRESSION; ATHEROSCLEROSIS; BRAIN ISCHEMIA; CONFERENCE PAPER; DIABETES MELLITUS; GENE; HUMAN; HYPERLIPIDEMIA; IMMUNE RESPONSE; INFLAMMATION; INNATE IMMUNITY; LIPID METABOLISM; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK FACTOR; STROKE;

ACUTE DISEASE; ANIMALS; ANTIGENS, CD36; ENCEPHALITIS; HUMANS; IMMUNITY, INNATE; LIPID METABOLISM; NEOVASCULARIZATION, PHYSIOLOGIC; STROKE;

ANIMALIA;

EID: 64549157610     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2009.05801.x     Document Type: Conference Paper

References (51)

1. Abumrad N. A., el-Maghrabi M. R., Amri E. Z., Lopez E. Grimaldi P. A. (1993) Cloning of a rat adipocyte membrane protein implicated in binding or transport of long-chain fatty acids that is induced during preadipocyte differentiation. Homology with human CD36. J. Biol. Chem. 268, 17665 17668.
2. Argmann C. A., Edwards J. Y., Sawyez C. G., O'Neil C. H., Hegele R. A., Pickering J. G. Huff M. W. (2005) Regulation of macrophage cholesterol efflux through hydroxymethylglutaryl-CoA reductase inhibition: a role for RhoA in ABCA1-mediated cholesterol efflux. J. Biol. Chem. 280, 22212 22221.
3. Benton C. R., Holloway G. P., Campbell S. E., Yoshida Y., Tandon N. N., Glatz J. F., Luiken J. J., Spriet L. L. Bonen A. (2008) Rosiglitazone increases fatty acid oxidation and fatty acid translocase (FAT/CD36) but not carnitine palmitoyltransferase I in rat muscle mitochondria. J. Physiol. 586, 1755 1766.
4. Bezaire V., Bruce C. R., Heigenhauser G. J., Tandon N. N., Glatz J. F., Luiken J. J., Bonen A. Spriet L. L. (2006) Identification of fatty acid translocase on human skeletal muscle mitochondrial membranes: essential role in fatty acid oxidation. Am. J. Physiol. Endocrinol. Metab. 290, E509 515.
5. Chabowski A., Gorski J., Calles-Escandon J., Tandon N. N. Bonen A. (2006) Hypoxia-induced fatty acid transporter translocation increases fatty acid transport and contributes to lipid accumulation in the heart. FEBS Lett. 580, 3617 3623.
6. Chen J., Li Y., Zhang R., Katakowski M., Gautam S. C., Xu Y., Lu M., Zhang Z. Chopp M. (2004) Combination therapy of stroke in rats with a nitric oxide donor and human bone marrow stromal cells enhances angiogenesis and neurogenesis. Brain Res. 1005, 21 28.
7. Chnari E., Nikitczuk J. S., Wang J., Uhrich K. E. Moghe P. V. (2006) Engineered polymeric nanoparticles for receptor-targeted blockage of oxidized low density lipoprotein uptake and atherogenesis in macrophages. Biomacromolecules 7, 1796 1805.
8. Cho S., Park E. M., Febbraio M., Anrather J., Park L., Racchumi G., Silverstein R. L. Iadecola C. (2005) The class B scavenger receptor CD36 mediates free radical production and tissue injury in cerebral ischemia. J. Neurosci. 25, 2504 2512.
9. Cho S., Szeto H. H., Kim E., Kim H., Tolhurst A. T. Pinto J. T. (2007) A novel cell-permeable antioxidant peptide, SS31, attenuates ischemic brain injury by down-regulating CD36. J. Biol. Chem. 282, 4634 4642.
10. Demers A., McNicoll N., Febbraio M., Servant M., Marleau S., Silverstein R. Ong H. (2004) Identification of the growth hormone-releasing peptide binding site in CD36: a photoaffinity cross-linking study. Biochem. J. 382, 417 424.
11. Ding G., Jiang Q., Zhang L., Zhang Z. G., Li L., Knight R. A., Ewing J. R., Wang Y. Chopp M. (2005) Analysis of combined treatment of embolic stroke in rat with r-tPA and a GPIIb/IIIa inhibitor. J. Cereb. Blood Flow Metab. 25, 87 97.
12. Dirnagl U. (2006) Bench to bedside: the quest for quality in experimental stroke research. J. Cereb. Blood Flow Metab. 26, 1465 1478.
13. El Khoury J. B., Moore K. J., Means T. K., Leung J., Terada K., Toft M., Freeman M. W. Luster A. D. (2003) CD36 mediates the innate host response to beta-amyloid. J. Exp. Med. 197, 1657 1666.
14. Febbraio M. Silverstein R. L. (2007) CD36: implications in cardiovascular disease. Int. J. Biochem. Cell Biol. 39, 2012 2030.
15. Febbraio M., Podrez E. A., Smith J. D., Hajjar D. P., Hazen S. L., Hoff H. F., Sharma K. Silverstein R. L. (2000) Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J. Clin. Invest. 105, 1049 1056.
16. Febbraio M., Hajjar D. P. Silverstein R. L. (2001) CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J. Clin. Invest. 108, 785 791.
17. Fuhrman B., Koren L., Volkova N., Keidar S., Hayek T. Aviram M. (2002) Atorvastatin therapy in hypercholesterolemic patients suppresses cellular uptake of oxidized-LDL by differentiating monocytes. Atherosclerosis 164, 179 185.
18. Gee J. M., Kalil A., Shea C. Becker K. J. (2007) Lymphocytes: potential mediators of postischemic injury and neuroprotection. Stroke 38, 783 788.
19. Guy E., Kuchibhotla S., Silverstein R. Febbraio M. (2007) Continued inhibition of atherosclerotic lesion development in long term Western diet fed CD36o /apoEo mice. Atherosclerosis 192, 123 130.
20. Hayashi T., Noshita N., Sugawara T. Chan P. H. (2003) Temporal profile of angiogenesis and expression of related genes in the brain after ischemia. J. Cereb. Blood Flow Metab. 23, 166 180.
21. Hazen S. L. (2008) Oxidized phospholipids as endogenous pattern recognition ligands in innate immunity. J. Biol. Chem. 283, 11527 11531.
22. Hoebe K., Georgel P., Rutschmann S. et al. (2005) CD36 is a sensor of diacylglycerides. Nature 433, 523 527.
23. Jimenez B., Volpert O. V., Crawford S. E., Febbraio M., Silverstein R. L. Bouck N. (2000) Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat. Med. 6, 41 48.
24. Kernan W. N., Inzucchi S. E., Viscoli C. M., Brass L. M., Bravata D. M., Shulman G. I., McVeety J. C. Horwitz R. I. (2003) Impaired insulin sensitivity among nondiabetic patients with a recent TIA or ischemic stroke. Neurology 60, 1447 1451.
25. Kim E., Tolhurst A. T., Qin L. Y., Chen X. Y., Febbraio M. Cho S. (2008) CD36/fatty acid translocase, an inflammatory mediator, is involved in hyperlipidemia-induced exacerbation in ischemic brain injury. J. Neurosci. 28, 4661 4670.
26. Korge P., Honda H. M. Weiss J. N. (2003) Effects of fatty acids in isolated mitochondria: implications for ischemic injury and cardioprotection. Am. J. Physiol. Heart Circ. Physiol. 285, H259 269.
27. Kunz A., Abe T., Hochrainer K., Shimamura M., Anrather J., Racchumi G., Zhou P. Iadecola C. (2008) Nuclear factor-kappaB activation and postischemic inflammation are suppressed in CD36-null mice after middle cerebral artery occlusion. J. Neurosci. 28, 1649 1658.
28. Lam M. C., Tan K. C. Lam K. S. (2004) Glycoxidized low-density lipoprotein regulates the expression of scavenger receptors in THP-1 macrophages. Atherosclerosis 177, 313 320.
29. Langley B., Gensert J. M., Beal M. F. Ratan R. R. (2005) Remodeling chromatin and stress resistance in the central nervous system: histone deacetylase inhibitors as novel and broadly effective neuroprotective agents. Curr Drug Targets CNS Neurol Disord. 4, 41 50.
30. Lin T. N., Kim G. M., Chen J. J., Cheung W. M., He Y. Y. Hsu C. Y. (2003) Differential regulation of thrombospondin-1 and thrombospondin-2 after focal cerebral ischemia/reperfusion. Stroke 34, 177 186.
31. Llaverias G., Lacasa D., Vinals M., Vazquez-Carrera M., Sanchez R. M., Laguna J. C. Alegret M. (2004) Reduction of intracellular cholesterol accumulation in THP-1 macrophages by a combination of rosiglitazone and atorvastatin. Biochem. Pharmacol. 68, 155 163.
32. Marleau S., Harb D., Bujold K. et al. (2005) EP 80317, a ligand of the CD36 scavenger receptor, protects apolipoprotein E-deficient mice from developing atherosclerotic lesions. FASEB J. 19, 1869 1871.
33. Matzinger P. (2002) The danger model: a renewed sense of self. Science 296, 301 305.
34. Mollen K. P., Anand R. J., Tsung A., Prince J. M., Levy R. M. Billiar T. R. (2006) Emerging paradigm: toll-like receptor 4-sentinel for the detection of tissue damage. Shock 26, 430 437.
35. Moore K. J., Kunjathoor V. V., Koehn S. L., Manning J. J., Tseng A. A., Silver J. M., McKee M. Freeman M. W. (2005) Loss of receptor-mediated lipid uptake via scavenger receptor A or CD36 pathways does not ameliorate atherosclerosis in hyperlipidemic mice. J. Clin. Invest. 115, 2192 2201.
36. Nagy L., Tontonoz P., Alvarez J. G., Chen H. Evans R. M. (1998) Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 93, 229 240.
37. Pilitsis J. G., Coplin W. M., O'Regan M. H., Wellwood J. M., Diaz F. G., Fairfax M. R., Michael D. B. Phillis J. W. (2003) Measurement of free fatty acids in cerebrospinal fluid from patients with hemorrhagic and ischemic stroke. Brain Res. 985, 198 201.
38. Ratan R. R., Siddiq A., Aminova L., Lange P. S., Langley B., Ayoub I., Gensert J. Chavez J. (2004) Translation of ischemic preconditioning to the patient: prolyl hydroxylase inhibition and hypoxia inducible factor-1 as novel targets for stroke therapy. Stroke 35, 2687 2689.
39. Ricciarelli R., Zingg J. M. Azzi A. (2000) Vitamin E reduces the uptake of oxidized LDL by inhibiting CD36 scavenger receptor expression in cultured aortic smooth muscle cells. Circulation 102, 82 87.
40. Ruiz-Velasco N., Dominguez A. Vega M. A. (2004) Statins upregulate CD36 expression in human monocytes, an effect strengthened when combined with PPAR-gamma ligands Putative contribution of Rho GTPases in statin-induced CD36 expression. Biochem. Pharmacol. 67, 303 313.
41. Sampson M. J., Davies I. R., Braschi S., Ivory K. Hughes D. A. (2003) Increased expression of a scavenger receptor (CD36) in monocytes from subjects with Type 2 diabetes. Atherosclerosis 167, 129 134.
42. Savill J. (1997) Recognition and phagocytosis of cells undergoing apoptosis. Br. Med. Bull. 53, 491 508.
43. Siddiq A., Ayoub I. A., Chavez J. C. et al. (2005) Hypoxia-inducible factor prolyl 4-hydroxylase inhibition. A target for neuroprotection in the central nervous system. J. Biol. Chem. 280, 41732 41743.
44. Slevin M., Kumar P., Gaffney J., Kumar S. Krupinski J. (2006) Can angiogenesis be exploited to improve stroke outcome? Mechanisms and therapeutic potential. Clin. Sci. (Lond) 111, 171 183.
45. Su X., Maguire-Zeiss K. A., Giuliano R., Prifti L., Venkatesh K. Federoff H. J. (2007) Synuclein activates microglia in a model of Parkinson's disease. Neurobiol. Aging 29, 1690 1701.
46. Sugiura S., Yagita Y., Sasaki T., Todo K., Terasaki Y., Ohyama N., Hori M. Kitagawa K. (2007) Postischemic administration of HMG CoA reductase inhibitor inhibits infarct expansion after transient middle cerebral artery occlusion. Brain Res. 1181, 125 129.
47. Susztak K., Ciccone E., McCue P., Sharma K. Bottinger E. P. (2005) Multiple metabolic hits converge on CD36 as novel mediator of tubular epithelial apoptosis in diabetic nephropathy. PLoS Med. 2, e45.
48. Szeto H. H. (2006) Cell-permeable, mitochondrial-targeted, peptide antioxidants. AAPS J. 8, E277 283.
49. Yang D. Y., Pan H. C., Yen Y. J. et al. (2007) Detrimental effects of post-treatment with fatty acids on brain injury in ischemic rats. Neurotoxicology 28, 1220 1229.
50. Ziegler G., Harhausen D., Schepers C. et al. (2007) TLR2 has a detrimental role in mouse transient focal cerebral ischemia. Biochem. Biophys. Res. Commun. 359, 574 579.
51. Ziv Y., Finkelstein A., Geffen Y. et al. (2007) A novel immune-based therapy for stroke induces neuroprotection and supports neurogenesis. Stroke 38, 774 782.